Resolution Therapeutics

UK - EdinburghBiotechnology8 H-1B visas (FY2023)

Focus: Resolution Therapeutics is a UK-based biotech company specializing in macrophage cell therapy and gene therapy approaches, currently in early-stage development with a focused pipeline.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Resolution Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Resolution Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Study in Patients With Decompensated Liver Cirrhosis

Liver Cirrhosis

N/A

Clinical Trials (1)

NCT06380335Study in Patients With Decompensated Liver Cirrhosis

N/A

Help build intelligence for Resolution Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused specialization in macrophage cell therapy, an emerging and differentiated modality with limited competitor talent pools
Early-stage pipeline in high-value indications including end-stage liver disease and COVID-19, offering opportunity to shape program direction
UK-based location in Edinburgh provides access to strong academic biotech ecosystem and lower cost-of-living relative to US biotech hubs

Watch Out For

No active job openings listed, indicating company is not actively hiring or is in a scaled-back phase
Pre-revenue stage with unknown funding trajectory creates uncertainty around runway, salary competitiveness, and long-term viability
Limited publication output (0 listed) and sparse clinical trial portfolio suggest early, unproven science with low visibility in peer review

Generated by Claude from Resolution Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Heartfulness Meditation

Burnout

N/A

Clinical Trials (1)

NCT04968795Heartfulness Meditation and Corporate Burnout

N/A

RTX001

End-stage Liver Disease (ESLD)

Phase 1/2

Clinical Trials (1)

NCT06823713RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

Phase 1/2

Interleukin-7

COVID-19

Phase 2

Clinical Trials (1)

NCT04927169InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)

Phase 2

inhaled mannitol

Cystic Fibrosis

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Gastroenterology, Infectious Diseases

H-1B (2023): 8 approvals

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Gastroenterology

2 pipeline

Infectious Diseases

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

80%

Rate

Source: USCIS H-1B Employer Data Hub